We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Dried Blood Spot Used to Screen for Clinical Conditions

By LabMedica International staff writers
Posted on 30 Nov 2011
A rapid method can be used to simultaneously screen patients for a range of genetic and acquired clinical conditions from a single dried blood spot.

Collection of dried blood spots is less invasive for patients and the costs and biohazards associated with sample transport, processing, and storage are minimized. More...
The test uses mass spectrometry, a highly sensitive and specific technique, to simultaneously analyse proteins, enzymes, and metabolites in the blood, without the need for the large liquid blood samples currently used.

The test works by converting proteins to peptides and then using a mass spectrometer to select and accurately measure diagnostic metabolites and/or peptides. Liquid blood and urine samples can also be screened using the method.

Scientists have built on their innovative approaches to dried blood spot screening for inherited metabolic disease and sickle cell disease in newborn babies. This approach can now be used in the early detection and clinical monitoring of chronic health problems, including kidney and heart disease, and diabetes.

A spin-out company, SpotOn Clinical Diagnostics Ltd (London, United Kingdom) was launched by King's College London (United Kingdom) to provide both analytical services and technical support for other clinical laboratories, many of which already have appropriate mass spectrometry instrumentation, to offer this new method.

The new blood spot analysis method has many potential applications including screening babies for sickle cell disease and other clinically significant hemoglobinopathies; the current methods for antenatal screening for sickle cell disease and thalassaemia require fresh liquid blood samples, which are more expensive to process, store, and transport. The method has already been used to provide rapid diagnosis of a comprehensive range of inherited metabolic diseases in acutely ill children admitted to intensive care with life-threatening symptoms.

Presymptomatic screening for chronic health problems will introduce personalized clinical diagnostics and cost-effective early detection and monitoring of diabetes and kidney and heart disease.

The major advantages of the new method are that the measurements for proteins and metabolites can be done simultaneously with both high accuracy and sensitivity. Dried blood spots and/or dried urine spots offer significant cost savings in the logistics of sample collection, transport to the laboratory, sample processing, and storage.

Related Links:
SpotOn Clinical Diagnostics Ltd.
King's College London


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
New
Immunofluorescence Analyzer
IFA System
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.